Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Desai J, Gan H, Barrow C, Jameson M, Atkinson V, Haydon A, Millward M, Begbie S, Brown M, Markman B, Patterson W, Hill A, Horvath L, Nagrial A, Richardson G, Jackson C, Friedlander M, Parente P, Tran B, Wang L, Chen Y, Tang Z, Huang W, Wu J, Zeng D, Luo L, Solomon B

(2020), J Clin Oncol, 38(19), 2140-50

DOI: 10.1200/JCO.19.02654

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy

Owen CN, Shoushtari AN, Chauhan D, Palmieri DJ, Lee B, Rohaan MW, Mangana J, Atkinson V, Zaman F, Young A, Hoeller C, Hersey P, Dummer R, Khattak MA, Millward M, Patel SP, Haydon A, Johnson DB, Lo S, Blank CU, Sandhu S, Carlino MS, Larkin JMG, Menzies AM, Long GV

(2020), Ann Oncol, 31(8), 1075-82

DOI: 10.1016/j.annonc.2020.04.471

Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises

Bhave P, Haydon A

(2020), Australas J Dermatol, 61(3), 203-9

DOI: 10.1111/ajd.13309

Caution in the age of optimism; a salient lesson in advanced melanoma

Roberts HN, Haydon A

(2020), Ann Transl Med, 8(11), 720

DOI: 10.21037/atm.2020.01.125

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

Dummer R, Hauschild A, Santinami M, Atkinson V, Mandalà M, Kirkwood JM, Chiarion Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Gasal E, Tan M, Long GV, Schadendorf D

(2020), NEW ENGL J MED, 383(12), 1139-48

DOI: 10.1056/NEJMoa2005493

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C

(2020), J Clin Oncol, 38(33), 3925-36

DOI: 10.1200/JCO.20.02110

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma

Atkinson V, Khattak A, Haydon A, Eastgate M, Roy A, Prithviraj P, Mueller C, Brignone C, Triebel F

(2020), J Immunother Cancer, 8(2), e001681

DOI: 10.1136/jitc-2020-001681

A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia

Lickliter JD, Gan HK, Voskoboynik M, Arulananda S, Gao B, Nagrial A, Grimison P, Harrison M, Zou J, Zhang L, Luo S, Lahn M, Kallender H, Mannucci A, Somma C, Woods K, Behren A, Fernandez-Penas P, Millward M, Meniawy T

(2020), DRUG DES DEV THER, 14, 1177-89

DOI: 10.2147/DDDT.S243787

Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial

Ratnayake G, Reinwald S, Shackleton M, Moore M, Voskoboynik M, Ruben J, van Zelm MC, Yu D, Ward R, Smith R, Haydon A, Senthi S

(2020), INT J RADIAT ONCOL, 108(1), 150-6

DOI: 10.1016/j.ijrobp.2020.05.022

First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors

Geva R, Voskoboynik M, Dobrenkov K, Mayawala K, Gwo J, Wnek R, Chartash E, Long GV

(2020), CANCER-AM CANCER SOC, 126(22), 4926-35

DOI: 10.1002/cncr.33133

Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma

Yau WH, Ameratunga M

(2020), J Clin Pharm Ther, 45(5), 1172-4

DOI: 10.1111/jcpt.13112

Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials

Terbuch A, Tiu C, Candilejo IM, Scaranti M, Curcean A, Bar D, Estevez Timon M, Ameratunga M, Ang JE, Ratoff J, Minchom AR, Banerji U, de Bono JS, Tunariu N, Lopez JS

(2020), Clin Cancer Res, 26(18), 4805-13

DOI: 10.1158/1078-0432.CCR-20-0454

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

Ameratunga M, Braña I, Bono P, Postel-Vinay S, Plummer R, Aspegren J, Korjamo T, Snapir A, de Bono JS

(2020), Brit J Cancer, 123(12), 1730-6

DOI: 10.1038/s41416-020-01077-z

The kinase polypharmacology landscape of clinical PARP inhibitors

Antolin AA, Ameratunga M, Banerji U, Clarke PA, Workman P, Al-Lazikani B

(2020), SCI REP-UK, 10(1), 2585

DOI: 10.1038/s41598-020-59074-4

Metastatic melanoma presenting as intravenous tumour thrombus

Nguyen J, Clements W, McLean C, Haydon A, Moore M, Yap KS, Mar V, Shackleton M

(2020), J MED IMAG RADIAT ON, 64(6), 814-6

DOI: 10.1111/1754-9485.13019

Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass

Byron Y, Nott L, Shackleton M

(2020), Melanoma Res, 30(6), 625-7

DOI: 10.1097/CMR.0000000000000696

Parity reduces mammary repopulating activity but does not affect mammary stem cells defined as CD24 + CD29/CD49fhi in mice

Dall GV, Vieusseux J, Seyed-Razavi Y, Godde N, Ludford-Menting M, Russell SM, Ashworth A, Anderson RL, Risbridger GP, Shackleton M, Britt KL

(2020), BREAST CANCER RES TR, 183(3), 565-75

DOI: 10.1007/s10549-020-05804-1

Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma

Lynch FA, Katona L, Jefford M, Smith AB, Shaw J, Dhillon HM, Ellen S, Phipps-Nelson J, Lai-Kwon J, Milne D, Russell L, Dax V, Diggens J, Kent H, Button-Sloan A, Elliott J, Shackleton M, Burridge H, Ftanou M

(2020), J Clin Med, 9(9), 2969

DOI: 10.3390/jcm9092969

Cancer history and risk factors in healthy older people enrolling in the ASPREE clinical trial

Orchard, Suzanne G.; Lockery, Jessica E.; Gibbs, Peter; Polekhina, Galina; Wolfe, Rory; Zalcberg, John; Haydon, Andrew; McNeil, John J.; Nelson, Mark R.; Reid, Christopher M.; Kirpach, Brenda; Murray, Anne M.; Woods, Robyn L.; ,

(2020), CONTEMP CLIN TRIALS, 96), 106095

DOI: 10.1016/j.cct.2020.106095

Towards new models of cancer care in Australia: lessons from Victoria's response to the COVID-19 pandemic

Underhill, Craig; Parente, Phillip; McArthur, Grant; Haydon, Andrew; McLachlan, Sue Anne; Wong, Zee Wan; Segelov, Eva; ,

(2020), INTERN MED J, 50(10), 1282-1285.

DOI: 10.1111/imj.15012

1 2 3 4 5